China Pharma (CPHI) Competitors $1.68 +0.24 (+16.32%) Closing price 03:59 PM EasternExtended Trading$1.62 -0.05 (-3.28%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock CPHI vs. CYCC, MTEX, AIMD, LEXX, ATNF, ETHZ, SYBX, LSB, EDSA, and BLRXShould you be buying China Pharma stock or one of its competitors? The main competitors of China Pharma include Cyclacel Pharmaceuticals (CYCC), Mannatech (MTEX), Ainos (AIMD), Lexaria Bioscience (LEXX), 180 Life Sciences (ATNF), Flag Ship Acquisition (ETHZ), Synlogic (SYBX), LakeShore Biopharma (LSB), Edesa Biotech (EDSA), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical products" industry. China Pharma vs. Its Competitors Cyclacel Pharmaceuticals Mannatech Ainos Lexaria Bioscience 180 Life Sciences Flag Ship Acquisition Synlogic LakeShore Biopharma Edesa Biotech BioLineRx China Pharma (NYSE:CPHI) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership. Which has higher earnings & valuation, CPHI or CYCC? China Pharma has higher revenue and earnings than Cyclacel Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina Pharma$4.40M1.24-$3.08MN/AN/ACyclacel Pharmaceuticals$40K398.72-$11.21M-$839.58-0.01 Does the media favor CPHI or CYCC? In the previous week, China Pharma and China Pharma both had 1 articles in the media. Cyclacel Pharmaceuticals' average media sentiment score of 1.00 beat China Pharma's score of -1.00 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment China Pharma Negative Cyclacel Pharmaceuticals Positive Which has more volatility and risk, CPHI or CYCC? China Pharma has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Do analysts prefer CPHI or CYCC? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cyclacel Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders hold more shares of CPHI or CYCC? 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 17.3% of China Pharma shares are owned by company insiders. Comparatively, 51.2% of Cyclacel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is CPHI or CYCC more profitable? Cyclacel Pharmaceuticals has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Cyclacel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets China Pharma-85.56% -63.93% -31.42% Cyclacel Pharmaceuticals N/A -723.64%-145.51% SummaryCyclacel Pharmaceuticals beats China Pharma on 6 of the 11 factors compared between the two stocks. Get China Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CPHI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CPHI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPHI vs. The Competition Export to ExcelMetricChina PharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$5.46M$864.50M$5.77B$21.32BDividend YieldN/A4.84%6.67%3.52%P/E RatioN/A1.1475.6029.64Price / Sales1.2426.53555.1849.98Price / CashN/A19.5637.1124.13Price / Book2.396.7111.444.55Net Income-$3.08M-$4.20M$3.28B$999.70M7 Day Performance20.42%0.64%0.84%0.55%1 Month Performance7.37%11.58%7.15%5.67%1 Year Performance-90.44%28.09%59.65%15.62% China Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPHIChina Pharma0.1711 of 5 stars$1.68+16.3%N/A-92.8%$5.46M$4.40M0.00250Negative NewsShort Interest ↑Gap UpCYCCCyclacel Pharmaceuticals1.393 of 5 stars$7.69-6.6%N/A-97.1%$18.44M$40K-0.0114Positive NewsShort Interest ↓MTEXMannatech0.4347 of 5 stars$8.60-10.2%N/A+21.0%$18.21M$117.87M-4.22250Short Interest ↑Gap UpAIMDAinos0.4232 of 5 stars$3.66-4.2%N/A+19.0%$17.79M$20K-0.7340Short Interest ↑LEXXLexaria Bioscience3.1607 of 5 stars$0.89+0.6%$4.00+351.5%-71.9%$17.22M$460K-1.327Short Interest ↑ATNF180 Life Sciences0.322 of 5 stars$2.81-2.1%N/A+0.8%$16.97MN/A-0.197Positive NewsETHZFlag Ship AcquisitionN/A$2.67-5.0%N/AN/A$16.97MN/A-0.187Positive NewsGap DownSYBXSynlogicN/A$1.46+0.7%N/A-1.4%$16.96M$10K-18.2580Positive NewsLSBLakeShore Biopharma1.6433 of 5 stars$0.82+2.7%N/A-82.1%$16.61M$85.67M0.00773Positive NewsShort Interest ↓Gap DownEDSAEdesa Biotech1.2561 of 5 stars$2.34+0.9%$5.00+113.7%-41.3%$16.33MN/A-1.7720Positive NewsGap UpBLRXBioLineRx2.3725 of 5 stars$3.75-1.1%$26.00+593.3%-85.8%$16.16M$28.94M-0.4340 Related Companies and Tools Related Companies Cyclacel Pharmaceuticals Competitors Mannatech Competitors Ainos Competitors Lexaria Bioscience Competitors 180 Life Sciences Competitors Flag Ship Acquisition Competitors Synlogic Competitors LakeShore Biopharma Competitors Edesa Biotech Competitors BioLineRx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CPHI) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China Pharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
